RhumbLine Advisers’s Aratana Therapeutics, Inc. PETX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-66,578
| Closed | -$344K | – | 2986 |
|
|
2019
Q2 | $344K | Buy |
66,578
+4,290
| +7% | +$19.3K | ﹤0.01% | 2546 |
|
|
2019
Q1 | $224K | Buy |
62,288
+677
| +1% | +$2.93K | ﹤0.01% | 2704 |
|
|
2018
Q4 | $378K | Buy |
61,611
+20,326
| +49% | +$124K | ﹤0.01% | 2428 |
|
|
2018
Q3 | $241K | Sell |
41,285
-1,065
| -3% | -$5.32K | ﹤0.01% | 2636 |
|
|
2018
Q2 | $180K | Buy |
42,350
+6,260
| +17% | +$31.6K | ﹤0.01% | 2764 |
|
|
2018
Q1 | $159K | Sell |
36,090
-1,100
| -3% | -$4.91K | ﹤0.01% | 2652 |
|
|
2017
Q4 | $196K | Sell |
37,190
-11,514
| -24% | -$70.4K | ﹤0.01% | 2639 |
|
|
2017
Q3 | $299K | Buy |
48,704
+490
| +1% | +$3.1K | ﹤0.01% | 2557 |
|
|
2017
Q2 | $349K | Buy |
48,214
+6,800
| +16% | +$41.8K | ﹤0.01% | 2482 |
|
|
2017
Q1 | $219K | Buy |
41,414
+7,027
| +20% | +$47.4K | ﹤0.01% | 2625 |
|
|
2016
Q4 | $247K | Sell |
34,387
-62
| -0.2% | -$501 | ﹤0.01% | 2584 |
|
|
2016
Q3 | $322K | Buy |
34,449
+1,260
| +4% | +$10.5K | ﹤0.01% | 2447 |
|
|
2016
Q2 | $210K | Buy |
33,189
+1,315
| +4% | +$8.46K | ﹤0.01% | 2716 |
|
|
2016
Q1 | $176K | Buy |
31,874
+310
| +1% | +$1.17K | ﹤0.01% | 2774 |
|
|
2015
Q4 | $176K | Buy |
31,564
+4,515
| +17% | +$29.8K | ﹤0.01% | 2841 |
|
|
2015
Q3 | $229K | Buy |
27,049
+1,014
| +4% | +$17.2K | ﹤0.01% | 2708 |
|
|
2015
Q2 | $394K | Sell |
26,035
-205
| -0.8% | -$2.96K | ﹤0.01% | 2487 |
|
|
2015
Q1 | $420K | Buy |
26,240
+5,600
| +27% | +$99.6K | ﹤0.01% | 2398 |
|
|
2014
Q4 | $368K | Buy |
20,640
+2,125
| +11% | +$26.5K | ﹤0.01% | 2464 |
|
|
2014
Q3 | $186K | Hold |
18,515
| – | – | ﹤0.01% | 2792 |
|
|
2014
Q2 | $289K | Buy |
+18,515
| New | +$262K | ﹤0.01% | 2626 |
|
Other funds holding PETX
RhumbLine Advisers's PETX Position: Q3 2019 in Review
RhumbLine Advisers sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 66,578 shares — an estimated $344K sold.
RhumbLine Advisers first reported a position in PETX in Q2 2014 and held it in 21 quarters. The position peaked at $420K in Q1 2015. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.
- RhumbLine Advisers reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
- RhumbLine Advisers sold 66,578 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $344K.
- RhumbLine Advisers first reported a position in Aratana Therapeutics, Inc. in Q2 2014 and held it in 21 quarters.
- RhumbLine Advisers's Aratana Therapeutics, Inc. position peaked at $420K in Q1 2015.
- 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.
Based on RhumbLine Advisers's 13F filing for Q3 2019, filed 23 Oct 2019.